| Dr Laura K Barnett, MD | |
|
1115 Ronald Reagan Pkwy Ste 206, Avon, IN 46123-6911 | |
| (317) 217-2888 | |
| (317) 963-5285 |
| Full Name | Dr Laura K Barnett |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 17 Years |
| Location | 1115 Ronald Reagan Pkwy Ste 206, Avon, Indiana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1437317542 | NPI | - | NPPES |
| 200990250 | Medicaid | IN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 01067195A (Indiana) | Secondary |
| 207R00000X | Internal Medicine | 11013757A (Indiana) | Secondary |
| 208M00000X | Hospitalist | 01067195A (Indiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Indiana University Health | Indianapolis, IN | Hospital |
| Iu Health West Hospital | Avon, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Indiana Clinic Critical Care Llc | 3678600988 | 206 |
News Archive
Retinal damage due to diabetes is now considered the most common cause of blindness in working-age adults.
Fibrocell Science, Inc. a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that it has signed an agreement to establish a joint venture (JV) with Hefei Meifu Bio-Tech Limited Co. for developing and marketing autologous fibroblast therapies in Asia, excluding Japan. The JV will be called Fibrocell Science Asia Co. Ltd.
A $258 million HIV/AIDS prevention program in six Indian states may have prevented an estimated 100,000 infections from 2003 to 2008, researchers from the Public Health Foundation of India and the University of Washington suggest in a study published in the Lancet on Tuesday, the Associated Press/Washington Post reports.
Three drugs that are already approved by the Food and Drug Administration (FDA) or other international agencies can block the production of the novel coronavirus that causes COVID-19 in human cells, according to computational and pharmaceutical studies performed by UT Southwestern scientists.
› Verified 3 days ago
| Entity Name | Indiana Clinic Critical Care Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417285230 PECOS PAC ID: 3678600988 Enrollment ID: O20100419000408 |
News Archive
Retinal damage due to diabetes is now considered the most common cause of blindness in working-age adults.
Fibrocell Science, Inc. a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that it has signed an agreement to establish a joint venture (JV) with Hefei Meifu Bio-Tech Limited Co. for developing and marketing autologous fibroblast therapies in Asia, excluding Japan. The JV will be called Fibrocell Science Asia Co. Ltd.
A $258 million HIV/AIDS prevention program in six Indian states may have prevented an estimated 100,000 infections from 2003 to 2008, researchers from the Public Health Foundation of India and the University of Washington suggest in a study published in the Lancet on Tuesday, the Associated Press/Washington Post reports.
Three drugs that are already approved by the Food and Drug Administration (FDA) or other international agencies can block the production of the novel coronavirus that causes COVID-19 in human cells, according to computational and pharmaceutical studies performed by UT Southwestern scientists.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Laura K Barnett, MD 250 N Shadeland Ave, Indianapolis, IN 46219-4959 Ph: () - | Dr Laura K Barnett, MD 1115 Ronald Reagan Pkwy Ste 206, Avon, IN 46123-6911 Ph: (317) 217-2888 |
News Archive
Retinal damage due to diabetes is now considered the most common cause of blindness in working-age adults.
Fibrocell Science, Inc. a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that it has signed an agreement to establish a joint venture (JV) with Hefei Meifu Bio-Tech Limited Co. for developing and marketing autologous fibroblast therapies in Asia, excluding Japan. The JV will be called Fibrocell Science Asia Co. Ltd.
A $258 million HIV/AIDS prevention program in six Indian states may have prevented an estimated 100,000 infections from 2003 to 2008, researchers from the Public Health Foundation of India and the University of Washington suggest in a study published in the Lancet on Tuesday, the Associated Press/Washington Post reports.
Three drugs that are already approved by the Food and Drug Administration (FDA) or other international agencies can block the production of the novel coronavirus that causes COVID-19 in human cells, according to computational and pharmaceutical studies performed by UT Southwestern scientists.
› Verified 3 days ago
Dr. Joseph Tien-yo Lee, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1115 N Ronald Reagan Pkwy, Ste 206, Avon, IN 46123 Phone: 317-217-2888 Fax: 317-217-2999 | |
Divya Reddy Nallapuram, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1111 Ronald Reagan Pkwy, Avon, IN 46123 Phone: 317-217-3649 |